Impact Of Aerobic Exercise Combined With Flupentixol-melitracen On Cardiopulmonary Function And Exercise Tolerance In Coronary Heart Disease Patients With Anxiety And Depression After Percutaneous Coronary Intervention

Objective:To observe the impact of aerobic exercise combined with flupentixol-melitracen on cardiopulmonary function and exercise tolerance in coronary heart disease patients with anxiety and depression after percutaneous coronary intervention（PCI）.Methods:There were 120 hospitalized patients underwent PCI for the first time from May 2019 to September 2020 who scored 50～69 on the self-rating anxiety scale（SAS）and self-rating depression scale（SDS）,including 78 men and 42 female.Their ages were 35～78（55.05±8.69）years old.On the basis of conventional medications for coronary heart disease,the patients were randomly divided into four groups:A total of 30patients in the aerobic exercise combined with flupentixol-melitracen group（group A）were given 12 weeks of aerobic exercise and oral flupentixol-melitracen tablets.1 tablet each time and twice a day,once in the morning and once in the middle of the day;A total of 30 patients in the aerobic exercise group（group B）were given 12 weeks of aerobic exercise and oral placebo.1 tablet each time and twice a day,once in the morning and once in the middle of the day;A total of 30 patients in the flupentixol-melitracen group（group C）were given 12 weeks of oral flupentixol-melitracen tablets.1 tablet each time and twice a day,once in the morning and once in the middle of the day;A total of 30 patients in the coronary heart disease conventional drug group（group D）were given oral placebo.1 tablet each time and twice a day,once in the morning and once in the middle of the day.The date of SAS score,SDS score,left ventricular ejection fraction（LVEF）,left ventricular end diastolic diameter（LVEDD）,peak oxygen uptake（peak VO₂）,peak oxygen pulse（peak O₂pulse）,anaerobic threshold（AT）and peak metabolic equivalent（peak MET）were collected before treatment and 12 weeks after treatment.Then compared the changes of each index in the four groups.Results:After treatment,SAS score and SDS score in the group D were significantly lower than before treatment（P<0.05）.There were no statistically significant differences in LVEF,LVEDD,peak VO₂,peak O₂pulse,AT and peak MET（P>0.05）.After treatment,SAS score and SDS score,LVEF,LVEDD,peak VO₂,peak O₂pulse,AT and peak MET in the group A,B,and C were significantly higher than before treatment（P<0.001）.Before treatment,SAS,SDS,LVEF,LVEDD,peak VO₂,peak O₂pulse,AT and peak MET of the four groups were compared and the differences were not statistically significant（P>0.05）.After treatment,SAS,SDS,LVEF,LVEDD,peak VO₂,peak O₂pulse,AT and peak MET of the four groups were compared,the differences were statistical（P<0.001）.Group A was compared with group B,group C,and group D,the differences were statistically significant（P<0.001）.Group B and group C were compared with group D,there were statistical differences（P<0.001）.But there were no statistical differences after compared Group B and C（P>0.05）.Conclusion:1.Compared with single treatment,the aerobic exercise combined with flupentixol-melitracen can significantly reduce anxiety and depression in patients with anxiety and depression after PCI.2.Aerobic exercise combined with flupentixol-melitracen may significantly improve the cardiac function in patients with anxiety and depression after PCI.3.Aerobic exercise combined with flupentixol-melitracen treatment may significantly improve the cardiopulmonary function and exercise tolerance in patients with anxiety and depression after PCI.